- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01931033
An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Male and female outpatients ages 11-17 years
- DSM-IV-TR PDD diagnosis of autistic disorder, Asperger's disorder, or PDD-NOS as established by clinical diagnostic interview and with the aid of the MGH ASD Symptom Checklist (MGH-ASD-SCL).
- At least moderate severity of ASD impairment as measured by a raw score of ≥80 on the SRS and a severity score of ≥4 on CGI-PDD.
- Participants and their parent/guardian must be able to speak and understand English sufficiently to comprehend the nature of the study and to allow for the completion of all study procedures required per protocol.
- Subjects and their parent/guardian must be considered reliable reporters.
- Each subject and their parent/guardian must understand the nature of the study and provide written informed assent/consent.
- Subjects must be able to participate in mandatory blood draws.
- Subjects with mood, anxiety, or disruptive behavior disorders will be allowed to participate in the study provided they do not meet any exclusionary criteria.
Exclusion Criteria
- IQ <85
- Total lack of spoken language
- DSM-IV-TR PDD diagnosis of Rett's disorder or childhood disintegrative disorder.
- Clinically unstable psychiatric conditions or judged to be at serious suicidal risk as determined by evaluating investigator.
- History of substance use (except nicotine or caffeine) within past 3 months
- Serious, stable or unstable systemic illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
- Subjects with severe hepatic impairment (LFTs > 3 times ULN) and those with severely impaired renal function (eGFR < 30).
- Pregnant or nursing females.
- Known hypersensitivity to oxytocin.
- Severe allergies or multiple adverse drug reactions.
- A non-responder or history of intolerance to oxytocin, after treatment at adequate doses as determined by the clinician.
- Subjects with significant nasal pathology (including atrophic rhinitis, recurrent nose bleeds, and history of hypophysectomy).
- Investigator and his/her immediate family defined as the investigator's spouse, parent, child, grandparent, or grandchild.
- Currently enrolled or recently participated (within the past 6 months) in a clinical trial of intranasal oxytocin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oxytocin
Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in ASD Symptoms Social Responsiveness Scales 2 (SRS-2) Scales From Baseline to Week 8
Time Frame: Week-8
|
Change in ASD symptoms as measured by change from baseline on the Social Responsiveness Scale 2 (SRS-2) scale. The SRS-2 is a 65-item rating scale completed that is used to measure the severity of autism spectrum symptoms as they occur in natural settings. The SRS-2 School Age form is completed by a parent or guardian for patients ages 9-17 and the SRS-2 Adult Self-report is completed by patients ages 18-59. Total raw scores range from 0 to 195, with higher scores indicating increased symptom severity. |
Week-8
|
Number of Participants With ≥30% Reduction in SRS Raw Score and CGI Improvement Scores of ≤ 2 at Week 8
Time Frame: Week-8
|
The SRS-2 is a 65-item rating scale completed that is used to measure the severity of autism spectrum symptoms as they occur in natural settings.
The SRS-2 School Age form is completed by a parent or guardian for patients ages 9-17 and the SRS-2 Adult Self-report is completed by patients ages 18-59.
Total raw scores range from 0 to 195, with higher scores indicating increased symptom severity.
The Clinical Global Impression Improvement scale (CGI-ASD-I) is a clinician rated measure of ASD improvement.
Improvement scores range from 1 (very much improved) to 7 (very much worse).
|
Week-8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Impression of PDD - Improvement (CGI-I)
Time Frame: Week-8
|
The CGI is a measure of illness severity, improvement, and efficacy of treatment (National Institute of Mental Health, 1985).
The score for Improvement ranges from 1 (very much improved) to 7 (very much worse).
|
Week-8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gagan Joshi, MD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-P-001548
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ASD
-
Sohag UniversityCompleted
-
University Rovira i VirgiliCompletedADHD | Probiotics | ASD | MicrobiotaSpain
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting
-
Jian-Jun OuRecruiting
-
Chen LiRecruiting
-
Xinhua Hospital, Shanghai Jiao Tong University...TerminatedASD Accompanied by Moderate to Severe Gastrointestinal SymptomsChina
-
Xinhua Hospital, Shanghai Jiao Tong University...Unknown
-
Centre Hospitalier Universitaire, AmiensRecruitingFunctional Magnetic Resonance Imaging | ASD | Social Cognition | Eye Tracking | Joint AttentionFrance
-
University of California, Los AngelesCompletedChildren at Risk for ASDUnited States
-
Hebrew University of JerusalemUnknown
Clinical Trials on Intranasal Oxytocin
-
University of Electronic Science and Technology...Completed
-
University of NebraskaNational Institute of Mental Health (NIMH)Terminated
-
Massachusetts General HospitalUnited States Department of DefenseRecruitingAutism Spectrum Disorder | Bone HealthUnited States
-
Icahn School of Medicine at Mount SinaiRecruitingBorderline Personality DisorderUnited States
-
MacDonald, Kai, M.D.CompletedAnxiety | BehaviorUnited States
-
OptiNose ASUniversity of OsloCompletedHealthy Male AdultsNorway
-
University of Electronic Science and Technology...Recruiting
-
Maria de las Mercedes Perez RodriguezJames J. Peters Veterans Affairs Medical Center; VISN 3 Mental Illness Research...TerminatedSchizophrenia | Schizoaffective Disorder | Bipolar Disorder | Autism Spectrum Disorder | Borderline Personality Disorder | Schizotypal Personality Disorder | SPD | BPDUnited States
-
University of Electronic Science and Technology...Unknown
-
University of Electronic Science and Technology...Completed